Polymeric Biomaterials in Drug-delivery Systems

Abstract

A substantial amount of progress has been made in the development of polymeric drug-delivery systems over the past two decades. As a result of polymer-mediated drug delivery, therapeutic substances are introduced into the body by means of a formulation or a device. The present study aimed to investigate the feasibility of developing new drug-delivery systems using biodegradable and bioreducible polymers. Future research prospects have been considered essential while developing application research in the practical field of pharmaceuticals. There are a number of polymers used in the pharmaceutical industry to formulate polymeric delivery systems for drugs, including polyarginine, polyglycolic acid, poly(lactic acid), poly(arginine), and hyaluronic acid. Polysaccharides and polyglycolic acids are also used to formulate polymeric delivery systems. In addition to 2-hydroxyethylmethacrylate (HEME) and accelerator polymers, biodegradable and bioabsorbable polymers have been studied for polymer-mediated drug delivery. A variety of polymeric drug-delivery systems have been investigated, including biomimetic polymers, drug-free macromolecular therapeutics, and biomimetic systems. Using vectors to deliver genes, polymeric gene-delivery systems are briefly discussed. Examples of viral vectors include DNA and RNA conjugates. These are not virus-like vectors. Polyethylenimine-conjugated bioreducible polymers and derivatives of ethylenimine are among the examples. Pharmaceutical companies are heavily investing in the research and development of polymeric drug-delivery systems, including natural and synthetic polymers. In recent years, biocompatible and bio-related copolymers as well as dendrimers have been developed that can deliver potent cancer-fighting drugs. Combining perspectives from synthetic and biological fields will lead to the development of a new paradigm for polymeric drug-delivery systems.